Related Experiment Videos
Providing a cure for beta thalassaemia major
L L Chan1, H P Lin, W A Ariffn
1Department of Paediatrics, Faculty of Medicine, University of Malaya, Lembah Pantai, Kuala Lumpur.
The Medical Journal of Malaysia
|May 17, 2002
Summary
Stem cell transplantation offers a cure for beta thalassaemia major when a matched sibling donor is available. This treatment led to a 76% cure rate in Malaysian children, avoiding transfusion complications.
Area of Science:
- Hematology
- Pediatric Medicine
- Transplantation Immunology
Background:
- Beta thalassaemia major requires lifelong treatment with blood transfusions and iron chelation, leading to complications.
- Transfusion-dependent anemia in beta thalassaemia major causes multi-organ damage and infection risks.
- Stem cell transplantation (SCT) is an alternative curative approach.
Purpose of the Study:
- To evaluate the efficacy of SCT in Malaysian children with beta thalassaemia major.
- To assess the cure rate and long-term outcomes of SCT using matched sibling donors.
Main Methods:
- Retrospective analysis of 38 Malaysian children with beta thalassaemia major.
- Treatment involved bone marrow or cord blood transplantation from matched sibling donors.
- Outcomes assessed included cure rates and survival.
Main Results:
- Twenty-nine out of 38 children (76%) achieved a cure after SCT.
- Matched sibling donor SCT resulted in a high cure rate and potential for normal life.
- This approach avoids the risks associated with chronic blood transfusions.
Conclusions:
- Stem cell transplantation with matched sibling donors is a highly effective first-line therapy for beta thalassaemia major.
- SCT offers a curative solution, significantly improving quality of life and survival.
- Early SCT referral when a matched donor is available is recommended.